Praxis Precision Medicines Has Path to 'Significant Upside,' RBC Says

MT Newswires Live11-14

Praxis Precision Medicines (PRAX) management remains confident in regulatory approval and the commercial prospects for ulixacaltamide, its investigational treatment for essential tremor, RBC Capital Markets said Thursday in a report.

At a presentation, the company said it is continuing preparations for a potential launch while expanding physician awareness of the treatment, according to RBC. Management also presented additional data that further reinforced ulixacaltamide's clinical profile, the report said.

Management additionally outlined a goal of building a leading neuroscience company capable of generating more than $20 billion in revenue, supported by its current portfolio and future pipeline opportunities, RBC said.

"Still, we remain focused on the near-term catalysts, and believe there is a path to significant upside, and continue to like the setup at these levels," the report said.

RBC has an outperform rating with speculative risk on Praxis shares and a $478 price target.

Price: 316.83, Change: -7.94, Percent Change: -2.44

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment